Alpha Tau's Alpha DaRT + Keytruda Combo Achieves 100% Response Rate in Head & Neck Cancer Study
DRTS has more than doubled off its 52-week low of $2.87.
Summary
Alpha Tau's Alpha DaRT combined with Keytruda achieved a 100% objective response rate in a study of nine evaluable head and neck cancer patients, significantly outperforming Keytruda's historical 19% response rate. Median overall survival was 18.2 months, compared to 12.3 months for Keytruda alone. This news follows the 6-K filed on July 21st, which broadly announced positive data from this study, but this article provides critical details and specific, highly impressive numbers. A 100% response rate and significantly extended survival, even in a small study, suggests a potentially transformative treatment for a difficult-to-treat cancer. The company is discussing a larger U.S. study of this combination with the FDA, which would be a key next step towards regulatory filing.
At the time of this announcement, DRTS was trading at $12.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $2.87 to $14.11. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: FinanceWire.